jeudi 12 septembre 2019

Onco Actu du 12 septembre 2019


3.1.1 PRÉVENTION - TABAC - E-CIGS



Trump administration prepares to ban flavored e-cigarettes [STAT]










Europe’s missing ‘vaping sickness’ [Politico]










Trump Administration Plans to Ban Flavored E-Cigarettes [NY Times]











Trump Administration Combating Epidemic of Youth E-Cigarette Use with Plan to Clear Market of Unauthorized, Non-Tobacco-Flavored E-Cigarette Products [HHS]











3.3.2 PRÉVENTION - VACCINS (OBSERVATION)



New evidence shows why the HPV vaccine is as important for boys as girls [STAT]










4.10 DÉP., DIAG. & PRONO. - POUMON



German Team Classifies Lung Tumors With Methylation Profiles, Machine Learning Methods [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



World-leading genomics project to give insights into health and disease [UKRI]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Roche-GE Partnership Integrates Molecular Data Into Navify Tumor Board [Genome Web]











4.9 DÉP., DIAG. & PRONO. - SEIN



More evidence screening mammograms not needed for many older women [Reuters]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Some cancer drugs miss their target. CRISPR could improve their aim [Science]











Cancer drugs don’t always work as intended, researchers warn [Cold Spring Harbor Lab]










Why Aren’t There Better Cancer Drugs? Scientists May Have Picked the Wrong Targets [NY Times]











Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials [Science Translational Medicine]











5.10 TRAITEMENTS - ESSAIS



When are RCTs Required for Breakthrough Drugs, HDEs? JAMA Study Investigates [RAPS]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



How Immunotherapy Might Be Used to Treat Heart Failure [NY Times]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy [Roche]











5.2 PHARMA



Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations [Merck KGaA]











Merck KGaA touts FDA 'breakthrough' status, blockbuster potential in bid to woo investors [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Public trust in drugmakers is at an all-time low. Can biopharma recover? [Biopharma Dive]











6.1 OBSERVATION



Measuring up: how does the UK compare internationally on cancer survival? [Cancer Research UK]










Britain slumps to bottom of cancer survival league tables – and is two decades behind some countries [The Telegraph]











Australia's high cancer survival rates attributed to earlier detection [The Guardian]











UK improves cancer survival, but is still behind other high-income countries [Cancer Research UK]











UK still behind in cancer survival despite recent surge [The Guardian]











6.6 PUBLICATIONS



New Report on Falsifiability and Reproducibility in Scientific Research [Digital Science]











Cite My Papers. Or Else. [In The Pipeline]











Elsevier investigates hundreds of peer reviewers for manipulating citations [Nature]











6.7 DMP, BIG DATA & APPLIS



Britain to use millions of NHS patients' histories to seek cures [The Guardian]